For Healthcare Professionals - International

CoreValve OUS

TAVI Platform

Performance that Matters TAVI

Latest News


Now Approved for Intermediate Risk Patients

CoreValve Evolut R TAVI system has received CE approval to expand the indication to include patients who are at high or greater risk for surgical aortic valve replacement OR are ≥75 years of age and at intermediate risk for surgical AVR (Society of Thoracic Surgeons operative risk score ≥4% or with an estimated hospital mortality ≥4% as assessed by the heart team).

Intermediate Risk Indication >


Superior Long-Term Clinical Outcomes

As presented at the ACC 2016 annual meeting, the CoreValve self-expanding, supra-annular valve continues to show a lower rate of stroke or mortality vs surgery, with better hemodynamic performance.

Learn More >


Superior Survival In High Risk Patients at 2 Years

Two year outcomes comparing TAVI with CoreValve to surgical aortic valve replacement (SAVR) in high risk patients was presented in a late-breaking session at ACC.15. As the first major TAVI trial to demonstrate superiority vs. SAVR, the findings show that the clinical advantages of TAVI with CoreValve are maintained over time.

CoreValve US Pivotal High Risk Study 2-Year Results >


Exceptional Survival Shown in 2-Year Results from the CoreValve US Pivotal Trial Extreme Risk Study

The results presented in a late breaking first reports session at TCT 2014 demonstrate the CoreValve system delivers high survival, a low and stable stroke rate and sustained hemodynamic and paravalvular leak performance in an extremely complex and frail patient population out to two years.

US Pivotal Trial Extreme Risk Study 2-Year Results >


CoreValve System Significantly Outperforms Surgical Valve Replacement at 1 Year In US Pivotal Trial

Results were presented in a late breaking clinical trial session at ACC.14 with simultaneous publication in the New England Journal of Medicine. Results demonstrate how the CoreValve design delivers performance that matters most to both physicians and their patients.

US Pivotal Trial High Risk Study Results >


CoreValve US Pivotal Trial Extreme Risk Study 1 Year Outcomes Published in JACC

The results demonstrate how the CoreValve design achieves high survival rates and low rates of stroke and paravalvular leakage in complex and frail patients.

US Pivotal Trial Extreme Risk Study Results >


Now CE Marked for Valve-in-Bioprosthetic Valve

CoreValve and CoreValve Evolut—the first and only TAVI devices to receive an indication for use in degenerative surgical bioprostheses—now provide options for patients at high operative risk for redo surgery.

Learn More >


CoreValve ADVANCE 1 Year Outcomes Presented at EuroPCR

New data presented at EuroPCR 2013 shows favorable 1 year outcomes with high survival rates, low and stable rates of stroke, and significant and sustained hemodynamic improvement.

ADVANCE 1 Year Outcomes >

Latest TAVI Developments


Sign up for periodic updates